Advisory Services Network, LLC Nektar Therapeutics Transaction History

Advisory Services Network, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.42 - $0.57 $1 - $1	3 New	3 $0
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $6 - $12	3 New	3 $0
Q4 2020 Feb 09, 2021	SELL	$15.77 - $19.03 $1,624 - $1,960	-103 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $1,708 - $2,553	103 New	103 $2,000
Q2 2020 Aug 10, 2020	SELL	$16.86 - $23.44 $61,572 - $85,602	-3,652 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $21,907 - $42,331	1,514 Added 70.81%	3,652 $65,000
Q4 2019 Feb 04, 2020	BUY	$15.87 - $23.12 $31,549 - $45,962	1,988 Added 1325.33%	2,138 $47,000
Q2 2019 Aug 01, 2019	SELL	$31.0 - $36.3 $6,200 - $7,259	-200 Reduced 57.14%	150 $0
Q1 2019 May 20, 2019	BUY	$31.58 - $46.35 $3,158 - $4,635	100 Added 40.0%	350 $12,000
Q4 2018 Feb 15, 2019	SELL	$30.43 - $56.65 $19,596 - $36,482	-644 Reduced 72.04%	250 $8,000
Q2 2018 Jul 27, 2018	BUY	$46.25 - $104.45 $39,035 - $88,155	844 Added 1688.0%	894 $45,000
Q1 2018 Apr 23, 2018	SELL	$57.4 - $108.44 $2,870 - $5,422	-50 Reduced 50.0%	50 $0
Q4 2017 Feb 08, 2018	BUY	$23.02 - $60.5 $2,302 - $6,050	100	100 $6,000

153

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $161M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.